VolitionRx Shares Supported by Positive Mayo Clinic Study on Nu.Q Biomarkers

VolitionRx Limited announced the publication of a peer-reviewed clinical study in the journal Shock, conducted in collaboration with the prestigious Mayo Clinic. The study demonstrates that the company's Nu.Q epigenetic biomarkers are significantly elevated in patients suffering from physical trauma. Specifically, the Nu.Q®H3.1 and Nu.Q®H3R8 tests showed even higher levels in patients who experienced severe complications following their injuries. This clinical validation from a world-renowned institution like the Mayo Clinic enhances the credibility of Volition's diagnostic platform. The findings suggest that these biomarkers could play a crucial role in identifying and monitoring trauma severity in acute care settings. Investors view this as a positive catalyst for VNRX, as it supports the company's ongoing efforts to commercialize its innovative diagnostic technology.